{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T04:48:49Z","timestamp":1794199729420,"version":"4.8.0"},"reference-count":14,"publisher":"American Academy of Pediatrics (AAP)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,4,1]]},"abstract":"<jats:sec>\n                  <jats:title>BACKGROUND AND OBJECTIVES<\/jats:title>\n                  <jats:p>Asthma is considered a precaution for use of quadrivalent live attenuated influenza vaccine (LAIV4) in persons aged \u22655 years because of concerns for wheezing events. We evaluated the safety of LAIV4 in children with asthma, comparing the proportion of children with asthma exacerbations after LAIV4 or quadrivalent inactivated influenza vaccine (IIV4).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>METHODS<\/jats:title>\n                  <jats:p>We enrolled 151 children with asthma, aged 5 to 17 years, during 2 influenza seasons. Participants were randomly assigned 1:1 to receive IIV4 or LAIV4 and monitored for asthma symptoms, exacerbations, changes in peak expiratory flow rate (PEFR), and changes in the asthma control test for 42 days after vaccination.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>RESULTS<\/jats:title>\n                  <jats:p>We included 142 participants in the per-protocol analysis. Within 42 days postvaccination, 18 of 142 (13%) experienced an asthma exacerbation: 8 of 74 (11%) in the LAIV4 group versus 10 of 68 (15%) in the IIV4 group (LAIV4-IIV4 = \u22120.0390 [90% confidence interval \u22120.1453 to 0.0674]), meeting the bounds for noninferiority. When adjusted for asthma severity, LAIV4 remained noninferior to IIV4. There were no significant differences in the frequency of asthma symptoms, change in PEFR, or childhood asthma control test\/asthma control test scores in the 14 days postvaccination between LAIV4 and IIV4 recipients. Vaccine reactogenicity was similar between groups, although sore throat (P = .051) and myalgia (P &amp;lt;.001) were more common in the IIV4 group.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>CONCLUSIONS<\/jats:title>\n                  <jats:p>LAIV4 was not associated with increased frequency of asthma exacerbations, an increase in asthma-related symptoms, or a decrease in PEFR compared with IIV4 among children aged 5 to 17 years with asthma.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1542\/peds.2021-055432","type":"journal-article","created":{"date-parts":[[2022,3,28]],"date-time":"2022-03-28T08:05:43Z","timestamp":1648454743000},"source":"Crossref","is-referenced-by-count":19,"title":["Safety of Live Attenuated Influenza Vaccine in Children With Asthma"],"prefix":"10.1542","volume":"149","author":[{"given":"Andrew G.","family":"Sokolow","sequence":"first","affiliation":[{"name":"Division of Allergy, Immunology, and Pulmonary Medicine"},{"name":"Departments ofPediatrics"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy P.","family":"Stallings","sequence":"additional","affiliation":[{"name":"Division of Allergy and Immunology"},{"name":"Department of Pediatrics"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolyn","family":"Kercsmar","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Cincinnati Children\u2019s Hospital Medical Center, Cincinnati, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theresa","family":"Harrington","sequence":"additional","affiliation":[{"name":"Immunization Safety Office, Centers for Disease Control and Prevention, Atlanta, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalia","family":"Jimenez-Truque","sequence":"additional","affiliation":[{"name":"Vanderbilt Vaccine Research Program, Vanderbilt University Medical Center, Nashville, Tennessee"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuwei","family":"Zhu","sequence":"additional","affiliation":[{"name":"Biostatistics"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine","family":"Sokolow","sequence":"additional","affiliation":[{"name":"Vanderbilt Vaccine Research Program, Vanderbilt University Medical Center, Nashville, Tennessee"},{"name":"Departments ofPediatrics"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. Anthony","family":"Moody","sequence":"additional","affiliation":[{"name":"Duke Human Vaccine Institute School of Medicine, Duke University, Durham, North Carolina"},{"name":"Department of Pediatrics"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth P.","family":"Schlaudecker","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Cincinnati Children\u2019s Hospital Medical Center, Cincinnati, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuel B.","family":"Walter","sequence":"additional","affiliation":[{"name":"Duke Human Vaccine Institute School of Medicine, Duke University, Durham, North Carolina"},{"name":"Department of Pediatrics"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary Allen","family":"Staat","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Cincinnati Children\u2019s Hospital Medical Center, Cincinnati, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen R.","family":"Broder","sequence":"additional","affiliation":[{"name":"Immunization Safety Office, Centers for Disease Control and Prevention, Atlanta, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C. Buddy","family":"Creech","sequence":"additional","affiliation":[{"name":"Vanderbilt Vaccine Research Program, Vanderbilt University Medical Center, Nashville, Tennessee"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"417","published-online":{"date-parts":[[2022,3,28]]},"reference":[{"issue":"4","key":"2022051017382623200_B1","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/j.jaci.2008.08.017","article-title":"Etiology of asthma exacerbations","volume":"122","author":"Sykes","year":"2008","journal-title":"J Allergy Clin Immunol"},{"issue":"11","key":"2022051017382623200_B2","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1016\/j.bbagen.2011.01.012","article-title":"Viruses and asthma","volume":"1810","author":"Dulek","year":"2011","journal-title":"Biochim Biophys Acta"},{"issue":"4","key":"2022051017382623200_B3","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1016\/j.jaci.2017.08.003","article-title":"Role of viral infections in the development and exacerbation of asthma in children","volume":"140","author":"Jartti","year":"2017","journal-title":"J Allergy Clin Immunol"},{"issue":"3","key":"2022051017382623200_B4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.15585\/mmwr.rr6703a1","article-title":"Prevention and control of seasonal influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices-United States, 2018-19 influenza season","volume":"67","author":"Grohskopf","year":"2018","journal-title":"MMWR Recomm Rep"},{"issue":"4","key":"2022051017382623200_B5","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1093\/jpids\/pit053","article-title":"Overview of influenza vaccines in children","volume":"2","author":"Lafond","year":"2013","journal-title":"J Pediatric Infect Dis Soc"},{"issue":"2","key":"2022051017382623200_B6","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1097\/01.inf.0000109392.96411.4f","article-title":"Safety of cold-adapted live attenuated influenza vaccine in a large cohort of children and adolescents","volume":"23","author":"Bergen","year":"2004","journal-title":"Pediatr Infect Dis J"},{"issue":"4","key":"2022051017382623200_B7","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1016\/j.jaci.2019.12.010","article-title":"Safety of live attenuated influenza vaccine (LAIV) in children with moderate to severe asthma","volume":"145","author":"Turner","year":"2020","journal-title":"J Allergy Clin Immunol"},{"issue":"30","key":"2022051017382623200_B8","doi-asserted-by":"crossref","first-page":"4055","DOI":"10.1016\/j.vaccine.2019.05.081","article-title":"Safety of guidelines recommending live attenuated influenza vaccine for routine use in children and adolescents with asthma","volume":"37","author":"Nordin","year":"2019","journal-title":"Vaccine"},{"key":"2022051017382623200_B9","doi-asserted-by":"crossref","first-page":"S94","DOI":"10.1016\/j.jaci.2007.09.029","article-title":"Expert panel report 3 (EPR-3): guidelines for the diagnosis and management of asthma-summary report 2007","volume":"120","author":"National Asthma Education and Prevention Program","year":"2007","journal-title":"J Allergy Clin Immunol"},{"issue":"2","key":"2022051017382623200_B10","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.jbi.2008.08.010","article-title":"Research electronic data capture (REDCap)--a metadata-driven methodology and workflow process for providing translational research informatics support","volume":"42","author":"Harris","year":"2009","journal-title":"J Biomed Inform"},{"issue":"10","key":"2022051017382623200_B11","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1097\/01.inf.0000237797.14283.cf","article-title":"Comparison of the efficacy and safety of live attenuated cold-adapted influenza vaccine, trivalent, with trivalent inactivated influenza virus vaccine in children and adolescents with asthma","volume":"25","author":"Fleming","year":"2006","journal-title":"Pediatr Infect Dis J"},{"issue":"20","key":"2022051017382623200_B12","doi-asserted-by":"crossref","first-page":"2668","DOI":"10.1016\/j.vaccine.2017.03.082","article-title":"Asthma exacerbations among asthmatic children receiving live attenuated versus inactivated influenza vaccines","volume":"35","author":"Ray","year":"2017","journal-title":"Vaccine"},{"issue":"4","key":"2022051017382623200_B13","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/j.anai.2017.01.030","article-title":"Live attenuated influenza vaccine use and safety in children and adults with asthma","volume":"118","author":"Duffy","year":"2017","journal-title":"Ann Allergy Asthma Immunol"},{"key":"2022051017382623200_B14","doi-asserted-by":"crossref","first-page":"h6291","DOI":"10.1136\/bmj.h6291","article-title":"Safety of live attenuated influenza vaccine in young people with egg allergy: multicentre prospective cohort study","volume":"351","author":"Turner","year":"2015","journal-title":"BMJ"}],"container-title":["Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/doi\/10.1542\/peds.2021-055432\/1284542\/peds_2021055432.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/doi\/10.1542\/peds.2021-055432\/1284542\/peds_2021055432.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,10]],"date-time":"2022-05-10T17:52:31Z","timestamp":1652205151000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.aap.org\/pediatrics\/article\/149\/4\/e2021055432\/185673\/Safety-of-Live-Attenuated-Influenza-Vaccine-in"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,28]]},"references-count":14,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2022,3,28]]},"published-print":{"date-parts":[[2022,4,1]]}},"URL":"https:\/\/doi.org\/10.1542\/peds.2021-055432","relation":{},"ISSN":["0031-4005","1098-4275"],"issn-type":[{"value":"0031-4005","type":"print"},{"value":"1098-4275","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,28]]},"article-number":"e2021055432"}}